secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMPEL PHARMACEUTICALS INC (—)
CIK:        0001445499
Form:       8-K
Filed at:   2023-04-17T23:59:59+00:00
Accession:  0000950170-23-013092
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Impel Pharmaceuticals receives Nasdaq delisting notifications for failing market value requirements
--------------------------------------------------------------------------------

- On April 11, 2023, Impel received Nasdaq notices for non-compliance with MVPHS ($15M minimum) and MVLS ($50M minimum) rules.
- Company has 180 calendar days (until October 9, 2023) to regain compliance by closing above thresholds for 10 consecutive business days.
- If unable to comply, Impel may request a hearing to appeal a potential delisting determination.
- Management will monitor market values and consider options to regain compliance, but no assurance of success.
- Common stock trades on Nasdaq under ticker IMPL; failure to comply could lead to delisting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445499/000095017023013092/0000950170-23-013092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445499/000095017023013092/impl-20230411.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-013092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer